Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.


Journal

BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 19 7 2018
medline: 21 8 2019
entrez: 19 7 2018
Statut: ppublish

Résumé

The Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2018) brought together 20 experts from 15 APAC countries to discuss the real-world application of consensus statements from the second APCCC held in St Gallen in 2017 (APCCC 2017). Differences in genetics, environment, lifestyle, diet and culture are all likely to influence the management of advanced prostate cancer in the APAC region when compared with the rest of the world. When considering the strong APCCC 2017 recommendation for the use of upfront docetaxel in metastatic castration-naïve prostate cancer, the panel noted possible increased toxicity in Asian men receiving docetaxel, which would affect this recommendation in the APAC region. Although androgen receptor-targeting agents appear to be well tolerated in Asian men with metastatic castration-resistant prostate cancer, access to these drugs is very limited for financial reasons across the region. The meeting highlighted that cost and access to contemporary treatments and technologies are key factors influencing therapeutic decision-making in the APAC region. Whilst lower cost/older treatments and technologies may be an option, issues of culture and patient or physician preference mean, these may not always be acceptable. Although generic products can reduce cost in some countries, costs may still be prohibitive for lower-income patients or communities. The panellists noted the opportunity for a coordinated approach across the APAC region to address issues of access and cost. Developments in technologies and treatments are presenting new opportunities for the diagnosis and treatment of advanced prostate cancer. Differences in genetics and epidemiology affect the side-effect profiles of some drugs and influence prescribing. As the field continues to evolve, collaboration across the APAC region will be important to facilitate relevant research and collection and appraisal of data relevant to APAC populations. In the meantime, the APAC APCCC 2018 meeting highlighted the critical importance of a multidisciplinary team-based approach to treatment planning and care, delivery of best-practice care by clinicians with appropriate expertise, and the importance of patient information and support for informed patient choice.

Identifiants

pubmed: 30019467
doi: 10.1111/bju.14489
doi:

Substances chimiques

Androgen Antagonists 0
Androstenes 0
Antineoplastic Agents 0
Docetaxel 15H5577CQD
abiraterone G819A456D0

Types de publication

Consensus Development Conference Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Pagination

22-34

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd.

Auteurs

Edmund Chiong (E)

Department of Urology, National University Hospital, National University Health System Singapore, Singapore City, Singapore.

Declan G Murphy (DG)

Division of Cancer Surgery, Peter MacCallum Cancer Centre Melbourne, Melbourne, VIC, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.

Hideyuki Akaza (H)

Strategic Investigation on Comprehensive Cancer Network, The University of Tokyo, Tokyo, Japan.

Nicholas C Buchan (NC)

Canterbury Urology Research Trust, Christchurch, New Zealand.
Canterbury District Health Board, Christchurch, New Zealand.

Byung Ha Chung (BH)

Department of Urology, Yonsei University College of Medicine, Seoul, Korea.

Ravindran Kanesvaran (R)

Division of Medical Oncology, National Cancer Centre Singapore, Singapore City, Singapore.

Makarand Khochikar (M)

Siddhi Vinayak Ganapati Cancer Hospital, Miraj, India.

Jason Letran (J)

Section of Urology, Department of Surgery, University of Santo Tomas, Manila, Philippines.

Bannakij Lojanapiwat (B)

Division of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Chi-Fai Ng (CF)

Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.

Teng Ong (T)

Division of Urology, Department of Surgery, University of Malaya, Kuala Lumpur, Malaysia.

Yeong-Shiau Pu (YS)

Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.

Marniza Saad (M)

Department of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Kathryn Schubach (K)

Australian and New Zealand Urology Nurses (ANZUNS), Melbourne, VIC, Australia.

Levent Türkeri (L)

Department of Urology, Acıbadem University, Istanbul, Turkey.

Rainy Umbas (R)

Department of Urology, University of Indonesia, Jakarta, Indonesia.

Vu Le Chuyen (V)

Department of Urology, Binh dan Hospital, Ho Chi Minh City, Vietnam.

Scott Williams (S)

Division of Radiation Oncology, Peter MacCallum Cancer Centre Melbourne, Melbourne, VIC, Australia.
ANZUP Cancer Trials Group, Sydney, NSW, Australia.

Ding-Wei Ye (DW)

Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Lifehouse, Camperdown, Sydney, NSW, Australia.

Ian D Davis (ID)

Monash University, Melbourne, VIC, Australia.
Eastern Health, Melbourne, VIC, Australia.
ANZUP Cancer Trials Group, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH